ContextPioglitazone is widely used for glycemic control in patients with type 2 diabetes
mellitus, but evidence is mixed regarding the influence of medications of this class on
cardiovascular outcomes. ObjectiveTo systematically evaluate the effect of pioglitazone on
ischemic cardiovascular events. Data Sources and Study SelectionA database containing
individual patient-level time-to-event data collected during pioglitazone clinical trials was
transferred from the drug's manufacturer for independent analysis. Trials were included if …